ARKG holdings

Computed by this site from the fund's SEC Form N-PORT filing; what the measure does not tell you · every fund in one table · hold it with other funds? X-ray the mix. Pricing: 100% at a quoted market price (level 1), 3 issuer countries.

ARKG's largest investment is Tempus AI Inc at 9.42% of net assets. Twist Bioscience Corp and Crispr Therapeutics AG Namen AKT follow; the three together are 27.32%. Ten companies are 59.16% of the fund; the other 23 share the rest. Among the 721 equity funds measured here, ARKG behaves like 21.2 holdings against a median of 42.4 — 2.0 times more concentrated than the median. Across 25 quarterly filings ARKG has held roughly steady since 2020-04-30 (19.3 then, 20.4 now). Between the 2026-01-30 and 2026-04-30 filings 5 positions were added and 7 dropped; 14.8% of the weight moved.

Each sentence is read from the fund's own SEC filing; the class median is computed across the comparable equity funds on this site. Nothing here is a view on the fund.

Between 2020-04-30 and 2026-04-30, ARKG went from behaving like 19.3 equally weighted positions to 20.4 — 6% more, while its top ten went from 61.39% to 58.96% of net assets. Read across the funds on the concentration-over-time table.

One row per filed reporting period, newest first, read from EDGAR. Quarterly because that is the public filing cadence. Rows marked * are published but held out of the comparison above; the methodology page says when and why.

The 15 largest of 33 positions in ARKG's Form N-PORT, weight as a share of net assets, securities-lending collateral excluded. Every position, every quarter: ARKG.csv.gz.

Share of ARKG's own investments by the issuer country the filer reported (incorporation, not revenue). Each country links to every fund that holds it.

Monthly total returns from Item B.5 of ARKG's own filings, 75 months on record. Not computed here and not from a price feed.

Cross-checked against a series computed separately from prices: median difference 0.10 percentage points over 75 months, which is roughly the distributions. Every month with the filing it came from: ARKG.json · all funds.

The fund lends its holdings, and Item B.4.a of the filing names every firm holding them. At 2026-07-31, $373m was out to 1 borrower.

The filing reports no cash collateral position against this loan. Collateral taken in a form the fund does not hold as a position does not appear in N-PORT, so this is silence rather than absence. What the collateral figure can and cannot show. Every quarter ARKG has filed, with each borrower: ARKG.json · all funds.

35 positions became 33: 5 added (3.9% of the fund at the later date), 7 dropped (5.2% at the earlier date). Half the sum of all weight changes, a turnover proxy: 14.8%. Positions are matched on identifiers, so a security whose identifier changed shows as one drop and one add. Every filing of ARKG compared this way, as a feed: changes.xml · all funds: filings received.

New: ALAMAR BIOSCIENCES INC (1.21%), BIONTECH SE (1.07%), ELI LILLY & COMPANY (0.95%), GENERATE BIOMEDICINES INC (0.52%), Goldman Sachs Financial Square Treasury Obligations Fund (0.13%). Gone: Amgen Inc (1.21%), Incyte Corp (1.07%), Vertex Pharmaceuticals Inc (0.96%), Caris Life Sciences Inc (0.74%), Veeva Systems Inc (0.66%), Standard BioTools Inc (0.34%).

99.82% equity, 0.18% short-term investment as filed; 100.0% carried at a quoted market price (fair-value level 1). Categories and levels are the filer's; what a low level-1 share does and does not mean is in the measure's page.

Every measured equity fund lined up by how many holdings it behaves like; these sit either side of ARKG (21.2). Same filings, same arithmetic. Position in this list says nothing about which fund is better.